Bank of New York Mellon Corp Has $59.76 Million Stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Bank of New York Mellon Corp lifted its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 0.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 481,386 shares of the specialty pharmaceutical company's stock after purchasing an additional 3,635 shares during the period. Bank of New York Mellon Corp owned about 0.79% of Jazz Pharmaceuticals worth $59,764,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also modified their holdings of the business. Quadrant Capital Group LLC increased its stake in Jazz Pharmaceuticals by 97.1% in the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after buying an additional 101 shares during the period. Elequin Capital LP raised its stake in shares of Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock valued at $26,000 after purchasing an additional 183 shares in the last quarter. CoreFirst Bank & Trust acquired a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at about $28,000. Allianz SE bought a new stake in Jazz Pharmaceuticals during the fourth quarter worth approximately $29,000. Finally, Parallel Advisors LLC raised its stake in shares of Jazz Pharmaceuticals by 85.6% in the first quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock valued at $32,000 after purchasing an additional 119 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on JAZZ. Needham & Company LLC reissued a "buy" rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 11th. Royal Bank Of Canada reduced their target price on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Piper Sandler restated an "overweight" rating and issued a $147.00 price target (down from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Deutsche Bank Aktiengesellschaft assumed coverage on Jazz Pharmaceuticals in a research report on Tuesday. They set a "buy" rating and a $152.00 target price for the company. Finally, Wall Street Zen cut Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $181.71.

Insider Buying and Selling

In other news, Director Seamus Mulligan bought 1,621 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The stock was acquired at an average cost of $103.00 per share, with a total value of $166,963.00. Following the completion of the purchase, the director owned 101,621 shares of the company's stock, valued at $10,466,963. This represents a 1.62% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total transaction of $107,630.00. Following the completion of the sale, the chief executive officer directly owned 436,973 shares of the company's stock, valued at approximately $47,031,403.99. The trade was a 0.23% decrease in their position. The disclosure for this sale can be found here. Insiders sold 2,500 shares of company stock worth $277,930 over the last quarter. 4.30% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Stock Up 0.7%

JAZZ traded up $0.83 on Tuesday, reaching $112.27. 457,280 shares of the company traded hands, compared to its average volume of 829,346. The stock's 50 day moving average price is $108.32 and its 200-day moving average price is $118.55. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $148.06. The company has a market cap of $6.79 billion, a price-to-earnings ratio of 14.97, a PEG ratio of 4.76 and a beta of 0.32. The company has a debt-to-equity ratio of 1.28, a current ratio of 3.38 and a quick ratio of 2.97.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The firm had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The company's revenue for the quarter was down .5% compared to the same quarter last year. During the same quarter last year, the business earned $2.68 EPS. On average, sell-side analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.